931 related articles for article (PubMed ID: 24457604)
21. Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium.
Loreti S; Thiele K; De Brucker M; Olsen C; Centelles-Lodeiro J; Bourgain C; Waelput W; Tournaye H; Griesinger G; Raes J; Vieira-Silva S; Arck P; Blockeel C; Mackens S
Hum Reprod; 2024 Feb; 39(2):403-412. PubMed ID: 38110714
[TBL] [Abstract][Full Text] [Related]
22. Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.
Liu JH; Soper D; Lukes A; Gee P; Kimble T; Kroll R; Mallick M; Chan A; Gillard P; Harrington A; Sniukiene V; Shulman LP
Obstet Gynecol; 2018 Nov; 132(5):1241-1251. PubMed ID: 30303900
[TBL] [Abstract][Full Text] [Related]
23. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
24. Esmya
Powell M; Dutta D
Womens Health (Lond); 2016 Nov; 12(6):544-548. PubMed ID: 29334010
[TBL] [Abstract][Full Text] [Related]
25. Preoperative medical therapy before surgery for uterine fibroids.
Lethaby A; Puscasiu L; Vollenhoven B
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD000547. PubMed ID: 29139105
[TBL] [Abstract][Full Text] [Related]
26. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
27. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
Donnez J; Courtoy GE; Donnez O; Dolmans MM
Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
[TBL] [Abstract][Full Text] [Related]
28. Fasting glucose measurement as a potential first step screening for glucose metabolism abnormalities in women with anovulatory polycystic ovary syndrome.
Veltman-Verhulst SM; Goverde AJ; van Haeften TW; Fauser BC
Hum Reprod; 2013 Aug; 28(8):2228-34. PubMed ID: 23739218
[TBL] [Abstract][Full Text] [Related]
29. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study.
Cameron ST; Berger C; Michie L; Klipping C; Gemzell-Danielsson K
Hum Reprod; 2015 Jul; 30(7):1566-72. PubMed ID: 25994664
[TBL] [Abstract][Full Text] [Related]
30. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial.
Griesinger G; Blockeel C; Sukhikh GT; Patki A; Dhorepatil B; Yang DZ; Chen ZJ; Kahler E; Pexman-Fieth C; Tournaye H
Hum Reprod; 2018 Dec; 33(12):2212-2221. PubMed ID: 30304457
[TBL] [Abstract][Full Text] [Related]
31. Excess mortality in mothers of patients with polycystic ovary syndrome.
Louwers YV; Roest-Schalken ME; Kleefstra N; Roeters van Lennep J; van den Berg M; Fauser BC; Bilo HJ; Sijbrands EJ; Laven JS
Hum Reprod; 2014 Aug; 29(8):1780-6. PubMed ID: 24876175
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
33. Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials.
Griesinger G; Blockeel C; Pierzynski P; Tournaye H; Višňová H; Humberstone A; Terrill P; Pohl O; Garner E; Donnez J; Loumaye E
Hum Reprod; 2021 Mar; 36(4):1007-1020. PubMed ID: 33534895
[TBL] [Abstract][Full Text] [Related]
34. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
35. ESHRE guideline: endometriosis.
Becker CM; Bokor A; Heikinheimo O; Horne A; Jansen F; Kiesel L; King K; Kvaskoff M; Nap A; Petersen K; Saridogan E; Tomassetti C; van Hanegem N; Vulliemoz N; Vermeulen N;
Hum Reprod Open; 2022; 2022(2):hoac009. PubMed ID: 35350465
[TBL] [Abstract][Full Text] [Related]
36. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
38. Preconception predictors of gestational diabetes: a multicentre prospective cohort study on the predominant complication of pregnancy in polycystic ovary syndrome.
de Wilde MA; Veltman-Verhulst SM; Goverde AJ; Lambalk CB; Laven JS; Franx A; Koster MP; Eijkemans MJ; Fauser BC
Hum Reprod; 2014 Jun; 29(6):1327-36. PubMed ID: 24777850
[TBL] [Abstract][Full Text] [Related]
39. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
40. Good practice recommendations on add-ons in reproductive medicine†.
; Lundin K; Bentzen JG; Bozdag G; Ebner T; Harper J; Le Clef N; Moffett A; Norcross S; Polyzos NP; Rautakallio-Hokkanen S; Sfontouris I; Sermon K; Vermeulen N; Pinborg A
Hum Reprod; 2023 Nov; 38(11):2062-2104. PubMed ID: 37747409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
